BIO Earnings Date: Nov 4, 2026 (Estimated) — Bio-Rad Laboratories, Inc.
NYSE · Healthcare · Medical Devices
Updated
When is BIO's next earnings date?
Bio-Rad Laboratories, Inc. (BIO) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:15 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $2.23 on revenue of $649.9M.
How did BIO do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), Bio-Rad Laboratories, Inc. posted EPS of $2.62 versus the $1.75 estimate, a beat of 40.9%. Revenue was $651.0M against a $624.0M estimate. The stock's 1-day post-earnings move was +4.5%.
How much does BIO stock move after earnings?
BIO beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.4% (up or down) in the day after earnings.
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | 1.75 | 2.62 | +40.86% | $651.0M | ✅ Beat | +4.50% | +7.02% | +16.71% |
| 2026-04-30 | Q1 2026 | 2.14 | 1.89 | -11.68% | $592.1M | ❌ Miss | -8.41% | -8.14% | +9.05% |
| 2026-02-12 | Q4 2025 | 2.65 | 2.51 | -5.28% | $693.2M | ❌ Miss | -12.26% | -7.22% | -10.66% |
| 2025-10-29 | Q3 2025 | 2.08 | 2.26 | +8.65% | $653.0M | ✅ Beat | -4.65% | -2.96% | +1.69% |
| 2025-07-31 | Q2 2025 | 1.82 | 2.61 | +43.41% | $651.6M | ✅ Beat | +17.63% | +9.63% | +23.12% |
| 2025-02-13 | Q4 2024 | 2.88 | 2.90 | +0.69% | $667.5M | ✅ Beat | -9.53% | -8.58% | -16.11% |
| 2024-10-30 | Q3 2024 | 1.16 | 2.01 | +73.28% | $649.7M | ✅ Beat | +8.35% | +12.81% | +3.01% |
| 2024-08-01 | Q2 2024 | 2.01 | 3.11 | +54.73% | $638.5M | ✅ Beat | -1.56% | -3.78% | -1.15% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $651.0M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Clinical Diagnostics | 61.3% | $399.0M | +2.6% | $392.6M | $356.8M | $388.8M | $391.2M |
| Life Science | 38.7% | $252.0M | -4.1% | $275.0M | $228.6M | $262.8M | $261.8M |
By region
Q2 FY26 · $651.0M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 39.2% | $255.5M | -4.3% | $258.2M | $241.7M | $266.9M | $270.0M |
| Europe | 35.2% | $229.2M | +5.5% | $221.7M | $199.8M | $217.2M | $222.2M |
| Asia Pacific | 18.7% | $121.8M | -3.6% | $146.3M | $104.1M | $126.4M | $121.0M |
| Americas | 6.8% | $44.5M | +8.3% | $41.3M | $39.8M | $41.1M | $39.8M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.